January 13, 2026|Press
2026 Year of ‘Clarity’ for US Beauty? Regulatory Reform, FDA Enforcement Strategy Coming Into Focus
By: Eileen Francis
“In addition to looking ahead, several attorneys and consultants reflected on how their predictions in last year’s “HBW Insight” piece projecting on the year ahead aligned with the reality of 2025.
Marissa Alkhazov, Partner and chair of the FDA Regulatory Compliance Group for Buchalter
2026 will be a year of regulatory reckoning. The New Year has arrived and the beauty industry is operating in a fundamentally different regulatory and litigation environment. MoCRA implementation continues to move from theory to enforcement, with FDA oversight expanding around facility registration, product listings, adverse event reporting, and ingredient transparency.”
To read the full article as published by HBW Insight, click here.*
*Subscription may be required.
